infectiousness

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 Inhibition of a BDV Infection with Amantadine Sulfate in vitro Treatment of rabbit brain cells either with amantadine sulfate (continuous line) or meso-inositol (broken line) for one hour before their infection (100±10 ffu/mL) with a human BDV strain (BDV-Hu1) * appropriate daily therapeutic dose of amantadine sulfate in mg, administered to the patient FIG. 2 Inhibition of BDV replication by amantadine sulfate Decrease in infectiousness 1) in human oligodendroglia (OL) cells, persistently infected with BDV-Hu-H1, which were treated for 6 days with 1.2 ?g/mL of amantadine sulfate, and 2) in freshly infected OL cells, which were treated with the same dose for 24 hours before the infection and then for a further 6 days, in comparison with untreated control samples. faded in: cell growth of not-infected OL cells with (solid line) and without (broken line) amantadine sulfate (1.2 ?g) FIG. 3 Virus Clearance After Treatment with Amantadine Sulfate is Interrupted Decrease in virus titer in a human oligodendroglia (OL) cell line, which was freshly infected with BVD-Hu-H1, treated for 6 days with 1.2 ?g/mL of amantadine sulfate and subsequently kept untreated (broken line) for a further 8 days and subjected to daily passages (1:2) in comparison to freshly infected OL cells, which were, however, not treated over the whole period.

Vor kurzem konnten von den Anmeldern in Blutproben psychisch kranker Patienten während akuter depressiver Phasen Virusproteine und genetisches Material des Borna Disease Virus (BDV) gefunden werden, eines eingehüllten, nicht-segmentierten Einzelstrang-RNA-Virus negativer Polarität, von dem bekannt ist, daß es bei Tieren psychische, zum Teil depressionsartige Symptome auslöst. Das infektiöse humane BDV konnte aus dem Blut von Patienten mit unterschiedlichen Ausprägungsformen von Affektkrankheiten isoliert werden (L. Bode in Curr Topics Microbiol Immun 1995, , 103 - 130; L. Bode, W. Zimmermann, R. Ferszt, F. Steinbach, H. Ludwig, Nature Med. 1995, , 232 - 236; L. Bode, R. Dürrwald, F. A. Rantam, R. Ferszt, H. Ludwig, Mol. Psychiatry 1996 (3): 200 - 212).